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Abstract
Background: Thyroid nodules are common, and most are benign. Given the risk of false-negative cytology (i.e. malignancy),
follow-up is recommended after 1–2 years, though this recommendation is based solely on expert opinion. Sonographic
appearance may assist with planning, but is limited by large inter-observer variability. We therefore compared the safety and
efficacy of long- versus short-interval follow-up after a benign initial aspiration, regardless of sonographic appearance.
Methods: This study evaluated all patients referred to the Brigham and Women’s Hospital Thyroid Nodule Clinic, between
1999 and 2010, with a cytologically benign nodule >1 cm and who had returned for follow-up sonographic evaluation.
Despite standard clinical recommendations, variation in patient compliance resulted in variable follow-up intervals from time
of initial aspiration to the first repeat evaluation. Main outcome measures included nodule growth, repeat fine needle
aspiration (FNA), thyroidectomy, malignancy, and disease-specific mortality.
Results:We evaluated 1,254 patients with 1,819 cytologically benign nodules, with a median time to first follow-up of
1.4 years (range, 0.5–14.1 years). The longer the follow-up interval, the more nodules grew and the more repeat FNAs
were performed (P <0.001). The most clinical meaningful endpoints of malignancy or mortality, however, did not differ
between the various follow-up intervals. The risk of a thyroidectomy (usually because of compressive symptoms) increased
when time to first follow-up exceeded >3 years (4.9 % vs. 1.2 %, P = 0.0001), though no difference in malignancy risk was
identified (0.2–0.8 %, P= 0.77). No (0 %) thyroid cancer-specific deaths were identified in either cohort.
Conclusions: While expert opinion currently recommends repeat evaluation of a cytologically benign nodule at 1–2 years,
these are the first data to demonstrate that this interval can be safely extended to 3 years without increased mortality or
patient harm. Nodule growth can be expected, though detection of malignancies is unchanged. While replication of these
data in large prospective multicenter studies is needed, this extension in follow-up interval would reduce unnecessary visits
and medical interventions for millions of affected patients worldwide, leading to healthcare savings.
Please see related commentary article: http://dx.doi.org/10.1186/s12916-016-0559-9 and research article:
http://dx.doi.org/10.1186/s12916-015-0419-z.
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Background
Thyroid nodules are increasingly common, affecting
5–20 % of the adult population [1–3]. Once detected,
ultrasound (US) is recommended, often in conjunction
with fine needle aspiration (FNA). A benign cytological
result is obtained in 65–75 % of cases, most often leading
to a recommendation for conservative (i.e. non-surgical)
management. However, cytological examination is not
flawless and many studies confirm a modest, though
non-negligible 1–10 % risk of a false-negative cytology
(i.e. malignancy) [4]. Because of this, physicians have
long recommended continued follow-up of cytologically
benign nodules [5, 6].
However, the empirical evidence for this recommenda-
tion remains weak, as there are little data on the optimal
time interval for such a repeat evaluation, while other
investigations have suggested a negligible risk of disease-
specific mortality regardless of follow-up strategy [7].
Current guidelines recommend repeat evaluation after 1–2
years; however, this is based solely on expert opinion [5, 6].
Furthermore, it is unclear what specific findings at the time
of repeat evaluation should prompt concern or further
investigation, which has led to confusion and variability
in clinical practice.
The importance of establishing improved guidance
should not be underestimated. Thyroid nodules afflict
millions of patients worldwide, and most prove benign.
Despite this, follow-up and repeat assessment are ex-
tended over many years, with some undergoing lifelong
follow-up. Nodule growth can be expected over time,
though most often it does not signal malignant concern
[8, 9]. While US is superior to physical examination of
the neck [10, 11], such technology also exacerbates
concern regarding small changes in nodule size or par-
enchyma. In an era of increasing healthcare cost and
intervention, some have argued that overtreatment and
overdiagnosis of nodular thyroid disease is occurring
[2, 12, 13]. It is estimated that over 500,000 thyroid
nodule aspirates occur annually in the United States alone
(Medicare data) [14]; as 300,000–350,000 will prove be-
nign, millions of repeat assessments are mandated during
the years thereafter. Determining the optimal time interval
for such evaluations would reduce unnecessary anxieties,
while likely leading to fewer US examinations, repeat aspi-
rations, and thyroidectomies. Ultimately, patient morbidity
may be decreased while healthcare savings are realized.
At Brigham and Women’s Hospital, a prospective data-
base has been maintained from 1995 onward, tracking all
patients evaluated for nodular thyroid disease using US
examination and US-guidance for FNA. This affords a
unique opportunity to address this important follow-
up question. Specifically, while each patient with ini-
tially benign cytology was asked to return for repeat
thyroid assessment in 1 year, patient compliance with
this recommendation varied. Thus, some patients returned
for repeat sonographic assessment in less than 1 year, while
others were reassessed after much longer periods. Though
non-randomized, such variation is free of substantial refer-
ral bias. We therefore used this opportunity to determine
differences between short- and long-interval follow-up
strategies after initial benign cytology.
Methods
We reviewed the medical records of all patients referred
to the thyroid biopsy clinic of the Brigham and Women’s
Hospital, Boston, MA, between January 1999 and January
2010. We identified all euthyroid patients with a clinically-
relevant thyroid nodule (>1 cm) found to have initial be-
nign cytology. Previous analysis confirmed that this clinic
evaluates >95 % of all patients seeking thyroid nodule
evaluation in our healthcare system, thus limiting referral
bias. The Brigham and Women’s Hospital catchment gen-
erally includes the greater Boston area and southwestern
Massachusetts, including some patients from Rhode
Island and Connecticut. US evaluation was performed
by one of four radiologists with expertise in thyroid
evaluation, using a 6–15 mHz transducer (GE Logic 9,
GE Healthcare, Milwaukee, WI). The length, width
and depth of each nodule was documented, in addition
to its solid or cystic content. FNA was performed by
one of four thyroidologists under US guidance. A 25-gauge
needle was typically used to obtain three samples per nod-
ule, and FNA cytology was evaluated by a Brigham and
Women’s Hospital cytopathologist. Although much of the
study predates the Bethesda System for Reporting Thyroid
Cytopathology [15, 16], all Brigham and Women’s Hospital
cytopathologists were already using identical criteria later
adopted by the Bethesda System for Reporting Thyroid
Cytopathology. All thyroid FNAs were classified into
one of the following categories: non-diagnostic, negative for
malignant cells (benign), atypical cells of undetermined sig-
nificance (AUS), suggestive of a follicular or Hurthle cell
neoplasm, suspicious for malignancy, or positive for malig-
nancy. The vast majority of cytologically benign nodules
were followed conservatively, with regular sonographic as-
sessments. Patients were typically asked to return for repeat
thyroid assessment in 1 year.
For the purpose of this study, we took advantage of
the known variability in patient compliance with the
above recommendation, specifically acknowledging that
some patients return for repeat assessment in less than
1 year, while others were reassessed after much longer
periods. We therefore identified all patients with cyto-
logically benign thyroid nodules who pursued repeat
sonographic evaluation at some point following the diag-
nosis of a cytologically benign thyroid nodule, regardless
of time interval. Each patient was analyzed as a single
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subject with a follow-up interval defined as the time be-
tween first benign aspiration and their first repeat sono-
graphic evaluation, regardless if subsequent ultrasounds
were performed thereafter. This is because management
decisions made at subsequent follow-up visits are likely
influenced by previous visits, while our goal was to in-
vestigate the clinical outcomes as a function of various
time intervals through the first follow-up visit. Patients
whose first follow-up was less than 6 months after initial
benign aspiration were excluded, as such scenarios
were deemed unique and likely influenced by separate
factors.
Nodule measurements were documented at baseline and
at the follow-up visit. Other follow-up variables were also
collected, including if a repeat FNA or if thyroidectomy
were performed. We used our Electronic Medical Record
system to identify whether each patient was presently living
or deceased (and if so, the cause of death) to determine if
the detection of a malignancy at a delayed follow-up period
was associated with increased disease-specific mortality.
This protocol was approved by the Investigational Re-
view Board of the Brigham and Women’s Hospital (IDs
1999P002899 and 2000P000167). Individual written con-
sent was not required given the lack of intervention and
reporting of data in an individually non-identifiable way.
Statistical analyses
The follow-up time between the two visits was rounded
to the nearest whole month. We grouped subjects accord-
ing to follow-up time into one of five clinically relevant
quintiles as follows: 0.5–1 year, >1–2 years, >2–3 years,
>3–4 years, and >4 years. To determine change in size with
time, nodule volume was calculated by using the formula
for a rotational ellipsoid (length ×width × depth × π/6) [17].
We employed two commonly used criteria for defining
sonographic growth over time. The first was a volume in-
crease of 15 %, while the second was a volume increase of
50 % [5, 6]. Each group was assessed for statistically signifi-
cant nodule growth, repeat FNA, thyroidectomy, and risk
of malignancy using χ2 tests and logistic regression analyses.
These analyses were corrected for age and sex.
Finally, acknowledging that growth was an important
reason for repeat FNA and thyroidectomy, we sought to
identify the determinants of benign nodule growth. To
do so, the effects of patient (age, sex) and nodule charac-
teristics (single versus multinodular, size, and solid versus
cystic parenchyma) on growth were tested using linear
and logistic regression analyses, correcting for follow-
up time. Sensitivity analyses were performed for the
continuous variables to identify the cut-off with the
strongest effects. Statistical analysis was performed using
SPSS version 22 (SPSS IBM, New York), and P values <0.05
were considered significant.
Results
Over a 10 year period, there were 34 patients with follow-
up periods <6 months, and 88 patients who had initial
surgery as the nodule was large (mostly >5 cm). There
were no thyroidectomies because of suspicious US features
or family history of thyroid carcinoma. In total, 1,372 pa-
tients with 2,006 cytologically benign thyroid nodules met
entry criteria and were analyzed. We excluded patients
aged <20 years (n = 43 nodules), given the uniqueness of
this population and potential selection bias [18]. Overall,
144 separate nodules were excluded because initial
follow-up was less than 6 months. This resulted in a final
population of 1,819 nodules, as shown in Table 1. As ex-
pected, the population was predominantly female (89.8 %)
with a mean age of 52.5 years. Thyroid nodule size aver-
aged 2.1 cm. These baseline characteristics were not asso-
ciated with follow-up time (all P >0.05).
The proportion of nodules identified in each follow-up
quintile is as follows: 0.5–1 year follow-up, n = 489
nodules; >1–2 years follow-up, n = 715 nodules; >2–3
years follow-up, n = 249 nodules; >3–4 years follow-up,
n = 143 nodules; >4 years follow-up, n = 223 nodules.
Comparisons of the risk of nodule growth, repeat FNA
or thyroidectomy, identification of a thyroid cancer (i.e.
false-negative cytology), and thyroid cancer-attributable
mortality are shown in Table 2. With longer follow-up
intervals, more nodules demonstrated growth, using both
the 15 % and 50 % volumetric cut-offs. This resulted in a
greater number of repeat aspirations, though there were
no differences in cytology results, even when follow-up
duration was lengthened. The number of thyroidectomies
Table 1 Baseline patient and nodule characteristics
Patients, n 1,254
Women, % 89
Age, years 52.5 (13.1)
Thyroid nodules, n 1,819
Maximum diameter, cm 2.1 (1.0)
Volume, cm3 3.7 (7.2)
Nodule characteristics, %:
<50 % Cystic 88.5
≥50 % Cystic 11.5
Years from initial benign aspirate to first follow-up:
Median (interquartile range) 1.4 (1.0–2.5) years
Range 0.5–14.1 years
0.5–1 year, n 489
1–2 years, n 715
2–3 years, n 249
3–4 years, n 143
>4 years, n 223
Age, maximum diameter and volume are shown as mean (SD)
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Table 2 Time interval until first follow-up of a benign thyroid nodule and the risk of growth, repeat FNAs, thyroidectomies, malignancies and mortality






Outcomes of repeat FNAs Thyroidectomies,
% (n)




0.5–1 489 30.3 (148) 8.6 (42) 5.1 (25) 21 Benign
1 AUS
3 Non-diagnostica
0.8 (4) 3 US Large size/growth
1 Compressive symptoms
0.2 (1) 0 (0)
>1–2 715 34.8 (249) 15.1 (108) 5.6 (40) 29 Benign
4 AUS
1 Susp. foll. neopl.
1 Susp. PTC
5 Non-diagnosticb
0.8 (6) 4 Abnormal repeat FNA
2 US Large size/growth
0.3 (2) 0 (0)
>2–3 249 40.2 (100) 19.7 (49) 8.8 (22) 18 Benign
1 AUS
1 Susp. foll. neopl.
1 Malignant
1 Non-diagnosticc
1.2 (3) 3 Abnormal repeat FNA 0.8 (2) 0 (0)
>3–4 143 50.3 (72) 34.3 (49) 18.9 (27) 22 Benign
3 AUS
2 Susp. foll. neopl.
4.9 (7) 3 Abnormal repeat FNA
2 Compressive symptoms
1 US Large size/growth
1 Afirma GEC positive
0.7 (1) 0 (0)
>4 (range 4.0–14.1) 223 52.5 (117) 35.0 (78) 19.3 (43) 35 Benign
3 AUS
1 Susp. Hurthle cell neopl.
1 Malignant
3 Non-diagnosticd
4.0 (9) 5 Compressive symptoms
2 Abnormal repeat FNA
1 US Large size/growth
1 Afirma GEC positive
0.4 (1) 0 (0)
P value <0.0001 <0.0001 <0.0001 0.0001 0.77 –
aAll nodules were >75 % cystic and had therefore a negligible low risk of malignancy and were not rebiopsied
bThree nodules were >75 % cystic and had therefore a negligible low risk of malignancy and were not rebiopsied. One nodule did not change in size during follow-up, and was therefore not rebiopsied. One nodule
was surgically removed (lobectomy) due to its large size (4.4 cm) and histological diagnosis confirmed a 3.3 cm follicular variant PTC (see Table 3 subject no. 3)
cNodule did not change in size during follow-up, and was therefore not rebiopsied
dOne nodule >75 % cystic and another 50–75 % cystic, which had therefore a negligible low risk of malignancy. The third nodule underwent total thyroidectomy as this patient had another nodule diagnosed with
malignant cytology. Histopathology confirmed a 1.1 cm follicular variant PTC, while the nodule with the non-diagnostic biopsy was histologically confirmed to be benign
FNA, Fine needle aspiration; AUS, Atypical cells of undetermined significance; PTC, Papillary thyroid carcinoma; GEC, Gene expression classifier. All malignancies were determined by histopathology and the malignancy












similarly increased, most notably when the follow-up inter-
val was longer than 3 years. Compressive symptoms were
the predominant indication for thyroidectomy. Only seven
malignancies were identified among 1,819 nodules, with
no significant difference in malignancy risk between the
cohorts. There were no (0 %) thyroid cancer related deaths
during a median follow-up of 7.7 (interquartile range,
5.5–10.5) years.
Table 3 shows the characteristics of the seven malig-
nancies. All were follicular variants of papillary thyroid
carcinoma (fvPTC). One patient (subject no. 1) underwent
a thyroidectomy for a symptomatic nodule, and a fvPTC
with focal capsular invasion and one scapular bone metas-
tasis was diagnosed. The metastasis showed an excellent
response to radioactive iodine treatment, and the patient
is currently disease free. All other malignancies demon-
strated very low risk characteristics. Specifically, all were
encapsulated or partially-encapsulated/well-circumscribed,
with only one nodule demonstrating extensive capsular in-
vasion. None demonstrated evidence of lymphovascular
invasion or extrathyroidal extension, and no lymph node
or distant metastases were identified. All patients are pres-
ently alive and considered disease free.
To further guide optimal follow-up strategies after a
benign aspiration, we sought to identify determinants of
benign nodule growth (Fig. 1). Sensitivity analyses were
performed to identify the cut-off with the strongest effects.
There were no effects of sex, multinodularity, or nodule
size on the risk of growth when using the 15 % volume in-
crease cut-off, nor when using the 50 % cut-off. However,
an age <50 years was associated with a higher risk of nodule
growth, both when using the 15 % cut-off (odd ratio (OR),
1.48; confidence interval (CI), 1.22–1.81; P <0.0001) as well
as the 50 % cut-off (OR, 1.61; CI, 1.26–2.07; P = 0.0002). A
solid parenchyma (<50 % cystic content) was also associ-
ated with a higher risk of growth, again both when using
the 15 % (OR, 2.91; CI, 2.02–4.18; P <0.0001) and 50 %
(OR, 1.91; CI, 1.21–3.02; P = 0.005) cut-offs. In order to
provide more insight, Fig. 2 depicts the absolute risk of
growth attributable to these factors.
Discussion
This is the first study to investigate the optimal time
interval for repeat evaluation of a benign thyroid nodule.
While a longer time interval is associated with greater
nodule growth, no detriments in health outcomes were
identified. Nodule growth led to a higher risk of repeat
FNA as well as thyroidectomy, but not an increased risk
of malignancy. As an increased rate of thyroidectomy was
only noted when follow-up exceeded 3 years, it appears
that symptomatic concerns related to nodule growth were
not clinically concerning with shorter follow-up intervals.
Importantly, follow-up intervals exceeding even 4 years
were not associated with a higher risk of detecting harmful
malignancies or adverse consequences. The risk of false-
negative cytology was similar among all cohorts, and
malignancy-related mortality was 0 % in the entire study
population. Together, these data show that most thyroid
nodules with initial benign cytology can be safely recom-
mended for repeat evaluation at a 3 year interval without
increased risk or likelihood of harm.
Little data are available on the optimal time interval for
repeat evaluation of a cytologically benign nodule. Negro
et al. [19] described 249 patients with benign nodular
disease who were followed for 5 years and documented
the timing of relevant events, including the risk of re-
peat FNA, thyroidectomy or newly diagnosed thyroid
malignancy. Unfortunately, due to the limited number
of patients, this study was underpowered to stratify for
follow-up time and did not investigate the outcomes at
various time intervals. Separately, we have previously
studied the disease-specific mortality attributable to
thyroid malignancies in a pilot population of patients
with cytologically benign nodules [7]. There were no
malignancy-related deaths, while thyroidectomies were
performed and malignancies identified at an average of
4.5 years. However, the design of that study was critically
different from the present one as it did not investigate the
outcomes of various follow-up intervals. It also did not in-
vestigate the risk of nodule growth, which is the driving
factor for most relevant interventions, including repeat
FNAs and thyroidectomies, as confirmed by the results of
the present study.
Given this important role for growth, we also sought
to find determinants of benign nodule growth in hopes
that this may further guide the clinician in personalizing
any follow-up interval using simple patient and US char-
acteristics. Age under 50 years and a solid parenchyma
were both associated with a substantially higher risk of
growth. While our results support a broad recommen-
dation for a 3 year follow-up interval, these sub-analyses
suggest that a longer interval may be considered for older
patients with more cystic nodules, or conversely slightly
shorter intervals for young patients with solid nodules.
Individual assessment incorporating all available data,
including patient preferences, remains paramount. In
this context it is of interest to note that the growth
rates of the nodules which turned out to be histologi-
cally malignant did not differ from the growth rates of
the nodules which were either cytologically (at repeat
FNA) or histologically benign, with mean increases of
119.5 % (45.8) (mean (SE)) for the malignant and
108.5 % (10.3) for the benign nodules (P = 0.82). How-
ever, a borderline significant difference in their largest
diameter at first visit was detected (3.1 (0.4) (mean (SE)) vs.
2.5 (0.9) cm, P = 0.08). Importantly, these data need to be
interpreted with caution as only seven malignancies were
detected in our cohort.
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Table 3 Description of the seven patients with false benign malignancies
Subject no. Time until first
follow-up, years
Nodule size at initial
aspiration, cm

























Encapsulated No No Disease free with
no recurrence




Encapsulated No No Disease free with
no recurrence





Encapsulated b No No Disease free with
no recurrence





Encapsulated No No Disease free with
no recurrence





Encapsulated No No Disease free with
no recurrence







No No Disease free with
no recurrence
aWith focal capsular invasion
bWith extensive capsular invasion
cMetastasis showed excellent reaction to radioactive iodine treatment












Recently, some studies have suggested that the presence
of certain sonographic characteristics (such as hypoecho-
genicity, irregular margins or microcalcifications) should
be used to determine the follow-up strategy of cytologic-
ally benign nodules [20, 21]. However, these studies are
retrospective and based on a limited number of nodules
with suspicious US characteristics (n = 93 and n = 102)
[20, 21], while others were not able to replicate these find-
ings [22]. Furthermore, various studies have shown that
interobserver agreement for most of these characteristics
is typically limited [23–26]. Thus, while helpful, it may
therefore be difficult to use these specific US characteris-
tics exclusively as a guide to optimal benign nodule
follow-up. The exact role of these specific US characteris-
tics in nodule care should therefore be determined in
future studies.
Strengths of this study include its large sample size
and the variation in time to first follow-up, which pro-
vides a robust comparison. We provide detailed data
on sonographic growth, repeat FNAs, thyroidectomies,












Nodule size (>3 cm)
Volume (>3 cm3)
Solid Parenchyma 




(<50 cystic) (<50 cystic)
Fig. 1 Determinants of benign nodule growth. Growth was calculated as the increase in volume between the baseline and first follow-up





























15% Volume increase 50% Volume increase
Age <50 yrs
P < 0.0001 












15% Volume increase 50% Volume increase
<50% CysticAge 50 yrs 50% Cystic
P = 0.005 
P < 0.0001 
Fig. 2 Effects of age <50 years and <50 % cystic content on the absolute risk of nodule growth. Growth was calculated as the increase in volume
between the baseline and first follow-up ultrasounds. Age analyses were corrected for follow-up time, cystic content and sex, and cystic content
analyses were corrected for follow-up time, age and sex
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histopathological results and mortality, and additionally
performed sub-analyses on determinants of benign nodule
growth. However, we similarly acknowledge limitations to
our study, including that it was performed in a single
center. Despite this, our clinic captures more than
95 % of patients undergoing thyroid evaluation in our
healthcare system, and all have been registered in our
database, which improves the generalizability of
our findings. While prospective, this study also does
not pursue a randomized intervention. The main con-
cern, therefore, would be that our follow-up intervals
were not randomly determined but rather influenced
by nodule-specific characteristics. However, this is
unlikely given that all patients with benign thyroid
nodules were provided similar recommendations for
routine 1-year follow-up. Furthermore, long interval
follow-ups were mostly attributable to patient compli-
ance and organizational delays – factors unlikely to
significantly bias our findings. Importantly, follow-up
time intervals were not associated with nodule size,
cystic content, age, or sex. It is therefore unlikely that
the variation in follow-up intervals was related to
nodule-specific factors. Furthermore, we cannot ex-
clude that part of the patients with faster growth pre-
sented earlier. However, as previously discussed,
growth did not seem to be a reliable indicator of malig-
nancy risk. Finally, we intentionally only included re-
sults from the first follow-up visit. This is because
management decisions made at subsequent follow-up
visits are likely influenced by previous visits, while our
goal was to investigate the clinical outcomes as a func-
tion of various time intervals through the first follow-
up visit. While this was therefore the correct design for
our main study outcomes, no recommendations on
timing of further follow-up visits could be made.
Conclusions
In summary, current guidelines recommend repeat
evaluation of a benign thyroid nodule after 1–2 years,
which is only based on expert opinion. This study sug-
gests that this recommendation can be safely extended
to 3 years without increased malignancy and mortality
risk, or likelihood of harm. Nodule growth can be ex-
pected, and therefore young patients, those experiencing
possible structural symptoms, or those with larger nod-
ules at baseline may be candidates for modified recom-
mendations. Conversely, even longer follow-up intervals
should be considered for older patients with predomin-
antly cystic nodules. While replication of these data in
large prospective multicenter studies is needed, this
extension in follow-up interval would reduce unneces-
sary visits and medical interventions for millions of
affected patients worldwide, leading to healthcare
savings.
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